Manufacture of messenger rna with kp34 polymerase
AssigneeSanofi Pasteur Limited
InventorsJianping CUI, Yaroslav MOROZOV
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and compositions for improving the in vitro transcription (IVT) of messenger RNA using Klebsiella phage KP34 RNA polymerase. In particular, the present disclosure provides a method for manufacturing messenger RNA comprising: (a) providing a DNA template comprising a nucleic acid sequence encoding an mRNA transcript for expression of a polypeptide or protein; (b) contacting the DNA template with a Klebsiella phage KP34 RNA polymerase under conditions suitable for IVT of the mRNA transcript.
Claims56
A method for manufacturing messenger RNA (mRNA) comprising:
- a. providing a DNA template comprising a nucleic acid sequence encoding an mRNA transcript for expression of a polypeptide or protein;
- b. contacting the DNA template with a Klebsiella phage KP34 RNA polymerase under conditions suitable for in vitro transcription (IVT) of the mRNA transcript.
The method of any one of the preceding claims, wherein the Klebsiella phage KP34 RNA polymerase comprises less than 5% enzymatically inactive aggregates.
The method of any one of the preceding claims, wherein the amino acid sequence of the Klebsiella phage KP34 RNA polymerase is at least 90% identical (e.g., at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or identical) to the amino acid sequence of SEQ ID NO:
- 1.
The method of any one of the preceding claims, wherein the Klebsiella phage KP34 RNA polymerase is present at a concentration ranging from 0.01-0.5 mg/mL.
The method of any one of the preceding claims, wherein the mRNA transcript comprises at least 500 ribonucleotides.
The method of any one of the preceding claims, wherein the amount of double-stranded RNA (dsRNA) comprised in the mRNA transcripts obtained in step (b) is below the limit of detection.
The method of any one of the preceding claims, wherein the amount of dsRNA generated in step (b) is at least 10-fold lower relative to a corresponding method using SP6 RNA polymerase or T7 RNA polymerase in place of the Klebsiella phage KP34 RNA polymerase.
The method of any one of the preceding claims, wherein the mRNA transcripts obtained in step (b) comprise less than 1% of dsRNA by weight.
The method of any one of the preceding claims, wherein 10% by weight or less of the mRNA transcripts obtained in step (b) comprise non-templated nucleic acids.
The method of any one of the preceding claims, wherein less than 10% by weight of the mRNA transcripts obtained in step (b) are abortive transcripts.
The method of any one of the preceding claims, wherein the method comprises synthesizing at least 100 mg of mRNA in a single batch.
The method of any one of the preceding claims, wherein the DNA template comprises a Klebsiella phage KP34 promoter sequence operably linked to the nucleic acid sequence encoding the mRNA transcript.
The method of any one of the preceding claims, wherein the DNA template is at a concentration of 0.05 mg/mL to 0.5 mg/mL.
The method of any one of the preceding claims, wherein the DNA template is linear or linearized.
The method of any one of the preceding claims, wherein IVT takes place in the presence of magnesium chloride (MgCl2).
The method of any one of the preceding claims, wherein IVT takes place in the presence of sodium chloride (NaCl).
The method of any one of the preceding claims, wherein IVT takes place in the presence of buffering agent.
The method of any one of the preceding claims, wherein IVT takes place in the presence of unmodified ribonucleotides.
The method of any one of the preceding claims, wherein IVT takes place in the presence of ribonucleotides, wherein each ribonucleotide is present at a concentration of 0.1 mM to 10 mM.
The method of any one of the preceding claims, wherein IVT takes place at a pH of 7.0 to 7.7.
The method of any one of the preceding claims, wherein IVT takes place at a temperature of 37° C. to 42° C.
The method of any one of the preceding claims, wherein IVT takes place over a period of 30 minutes to 6 hours.
The method of any one of the preceding claims, wherein IVT is terminated by addition of DNase I and a DNase I buffer.
The method of any one of the preceding claims, further comprising a step of purifying the mRNA transcripts obtained in step (b) from the KP34 RNA polymerase.
A composition comprising mRNA transcripts and Klebsiella phage KP34 RNA polymerase, wherein the composition comprises less than 1% of dsRNA by weight and wherein less than 10% of the mRNA transcripts by weight are abortive transcripts.
Dependencies are inferred from the claim text.